Linnea Malmgren1,2, Fiona E McGuigan1,3, Anders Christensson1,4, Kristina E Akesson5,6. 1. Department of Clinical Sciences Malmö, Clinical and Molecular Osteoporosis Research Unit, Lund University, Malmö, Sweden. 2. Department of Geriatrics, Skåne University Hospital, Malmö, Sweden. 3. Department of Orthopedics, Skåne University Hospital, Malmö, Sweden. 4. Department of Nephrology, Skåne University Hospital, Malmö, Sweden. 5. Department of Clinical Sciences Malmö, Clinical and Molecular Osteoporosis Research Unit, Lund University, Malmö, Sweden, kristina.akesson@med.lu.se. 6. Department of Orthopedics, Skåne University Hospital, Malmö, Sweden, kristina.akesson@med.lu.se.
Abstract
BACKGROUND/AIMS: Prospective data on age-related changes in kidney function are required, especially since the current Kidney Disease Improving Global Outcomes (KDIGO) definition has been suggested to classify a large number of elderly people with CKD. OBJECTIVE: This study, a complement to our previous Cr-based study in the same cohort, is aimed at evaluating cystatin C (cysC)-based changes in kidney function during aging in older women and analyzing the association between CKD and mortality through 10 years of follow-up. METHODS: cysC was available in 981 women from the Osteoporosis Prospective Risk Assessment (OPRA) cohort, all aged 75 years on entry. Reinvestigations were made after 5 (n = 685) and 10 years (n = 365). Kidney function was estimated (estimated glomerular filtration rate [eGFR]) using Chronic Kidney Disease Epidemiology Collaboration cysC and Caucasian, Asian, Pediatric, and Adult cysC equations and the change in function calculated. Women were staged equivalent to CKD stage 1, 2, 3a, or 3b-5 according to the KDIGO classification. Mortality risk was estimated for 5-year or 10-year follow-up time using Cox proportional hazard analyses (reference category, CKD stages 1 and 2). RESULTS: Mortality risk for women with the worst kidney function (CKD stages 3b-5) increased during both 5-year follow-up times compared to that for women in stages 1 and 2 (age 75-80 years: adjusted Hazard Ratio [HRadj] 3.9, 95% confidence interval [CI] 2.3-6.5; age 80-85 years: HRadj 1.7, 95% CI 1.0-2.7). In contrast, women in stage 3a had increased risk only in the first 5-year follow-up (HRadj 1.7, 95% CI 1.0-3.0, age 75-80 years). Change in kidney function amounted to a loss of 1.9 (±1.4) mL/min/1.73 m2 per year during the 10-year follow-up, and at age 85 years, 4 of every 5 women had an eGFR equivalent to CKD. CONCLUSION: In the future, an age-adapted definition of CKD, lowering the threshold for CKD in the elderly, may be beneficial to avoid overdiagnosis of CKD.
BACKGROUND/AIMS: Prospective data on age-related changes in kidney function are required, especially since the current Kidney Disease Improving Global Outcomes (KDIGO) definition has been suggested to classify a large number of elderly people with CKD. OBJECTIVE: This study, a complement to our previous Cr-based study in the same cohort, is aimed at evaluating cystatin C (cysC)-based changes in kidney function during aging in older women and analyzing the association between CKD and mortality through 10 years of follow-up. METHODS:cysC was available in 981 women from the Osteoporosis Prospective Risk Assessment (OPRA) cohort, all aged 75 years on entry. Reinvestigations were made after 5 (n = 685) and 10 years (n = 365). Kidney function was estimated (estimated glomerular filtration rate [eGFR]) using Chronic Kidney Disease Epidemiology Collaboration cysC and Caucasian, Asian, Pediatric, and Adult cysC equations and the change in function calculated. Women were staged equivalent to CKD stage 1, 2, 3a, or 3b-5 according to the KDIGO classification. Mortality risk was estimated for 5-year or 10-year follow-up time using Cox proportional hazard analyses (reference category, CKD stages 1 and 2). RESULTS:Mortality risk for women with the worst kidney function (CKD stages 3b-5) increased during both 5-year follow-up times compared to that for women in stages 1 and 2 (age 75-80 years: adjusted Hazard Ratio [HRadj] 3.9, 95% confidence interval [CI] 2.3-6.5; age 80-85 years: HRadj 1.7, 95% CI 1.0-2.7). In contrast, women in stage 3a had increased risk only in the first 5-year follow-up (HRadj 1.7, 95% CI 1.0-3.0, age 75-80 years). Change in kidney function amounted to a loss of 1.9 (±1.4) mL/min/1.73 m2 per year during the 10-year follow-up, and at age 85 years, 4 of every 5 women had an eGFR equivalent to CKD. CONCLUSION: In the future, an age-adapted definition of CKD, lowering the threshold for CKD in the elderly, may be beneficial to avoid overdiagnosis of CKD.
Authors: Alessandro Gasparini; Marie Evans; Josef Coresh; Morgan E Grams; Olof Norin; Abdul R Qureshi; Björn Runesson; Peter Barany; Johan Ärnlöv; Tomas Jernberg; Björn Wettermark; Carl G Elinder; Juan-Jesüs Carrero Journal: Nephrol Dial Transplant Date: 2016-10-13 Impact factor: 5.992
Authors: Anders Grubb; Masaru Horio; Lars-Olof Hansson; Jonas Björk; Ulf Nyman; Mats Flodin; Anders Larsson; Arend Bökenkamp; Yoshinari Yasuda; Hester Blufpand; Veronica Lindström; Ingrid Zegers; Harald Althaus; Søren Blirup-Jensen; Yoshi Itoh; Per Sjöström; Gunnar Nordin; Anders Christensson; Horst Klima; Kathrin Sunde; Per Hjort-Christensen; David Armbruster; Carlo Ferrero Journal: Clin Chem Date: 2014-05-14 Impact factor: 8.327
Authors: Li Fan; Andrew S Levey; Vilmundur Gudnason; Gudny Eiriksdottir; Margret B Andresdottir; Hrefna Gudmundsdottir; Olafur S Indridason; Runolfur Palsson; Gary Mitchell; Lesley A Inker Journal: J Am Soc Nephrol Date: 2014-12-19 Impact factor: 10.121
Authors: Pierre Delanaye; Kitty J Jager; Arend Bökenkamp; Anders Christensson; Laurence Dubourg; Bjørn Odvar Eriksen; François Gaillard; Giovanni Gambaro; Markus van der Giet; Richard J Glassock; Olafur S Indridason; Marco van Londen; Christophe Mariat; Toralf Melsom; Olivier Moranne; Gunnar Nordin; Runolfur Palsson; Hans Pottel; Andrew D Rule; Elke Schaeffner; Maarten W Taal; Christine White; Anders Grubb; Jan A J G van den Brand Journal: J Am Soc Nephrol Date: 2019-09-10 Impact factor: 10.121
Authors: Paul Gerdhem; Kaisa K Ivaska; Sari L Alatalo; Jussi M Halleen; Jukka Hellman; Anders Isaksson; Kim Pettersson; H Kalervo Väänänen; Kristina Akesson; Karl J Obrant Journal: J Bone Miner Res Date: 2003-12-22 Impact factor: 6.741
Authors: Elke S Schaeffner; Natalie Ebert; Martin K Kuhlmann; Peter Martus; Nina Mielke; Alice Schneider; Markus van der Giet; Dörte Huscher Journal: Clin J Am Soc Nephrol Date: 2022-07-18 Impact factor: 10.614